instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Periventricular leukomalacia'. | Waldenstrom Macroglobulinemia Manifesting as Acute Kidney Injury and Bing-Neel Syndrome With Excellent Response to Ibrutinib.
Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma associated with a monoclonal immunoglobulin M protein. Extranodal involvement in WM is not very common. In this article, we pre... | CYCLOPHOSPHAMIDE, DEXAMETHASONE, RITUXIMAB | DrugsGivenReaction | CC BY-NC | 34078157 | 19,420,931 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia aspiration'. | Waldenstrom Macroglobulinemia Manifesting as Acute Kidney Injury and Bing-Neel Syndrome With Excellent Response to Ibrutinib.
Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma associated with a monoclonal immunoglobulin M protein. Extranodal involvement in WM is not very common. In this article, we pre... | CYCLOPHOSPHAMIDE, DEXAMETHASONE, RITUXIMAB | DrugsGivenReaction | CC BY-NC | 34078157 | 19,420,931 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Seizure'. | Waldenstrom Macroglobulinemia Manifesting as Acute Kidney Injury and Bing-Neel Syndrome With Excellent Response to Ibrutinib.
Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma associated with a monoclonal immunoglobulin M protein. Extranodal involvement in WM is not very common. In this article, we pre... | CYCLOPHOSPHAMIDE, DEXAMETHASONE, RITUXIMAB | DrugsGivenReaction | CC BY-NC | 34078157 | 19,420,931 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute respiratory distress syndrome'. | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | CYCLOPHOSPHAMIDE, DOXORUBICIN, LAMIVUDINE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19'. | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | CYCLOPHOSPHAMIDE, DOXORUBICIN, LAMIVUDINE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | CYCLOPHOSPHAMIDE, DOXORUBICIN, LAMIVUDINE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lymphopenia'. | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | CYCLOPHOSPHAMIDE, DOXORUBICIN, LAMIVUDINE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mantle cell lymphoma'. | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | CYCLOPHOSPHAMIDE, DOXORUBICIN, LAMIVUDINE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | CYCLOPHOSPHAMIDE, DOXORUBICIN, LAMIVUDINE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | CYCLOPHOSPHAMIDE, DOXORUBICIN, LAMIVUDINE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | 06 COURSES | DrugDosageText | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
What was the dosage of drug 'DOXORUBICIN'? | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | 06 COURSES | DrugDosageText | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
What was the dosage of drug 'PREDNISONE'? | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | 06 COURSES | DrugDosageText | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
What was the dosage of drug 'VINCRISTINE'? | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | 06 COURSES | DrugDosageText | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
What was the outcome of reaction 'Acute respiratory distress syndrome'? | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | Fatal | ReactionOutcome | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
What was the outcome of reaction 'COVID-19'? | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | Fatal | ReactionOutcome | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
What was the outcome of reaction 'Disease progression'? | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | Fatal | ReactionOutcome | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
What was the outcome of reaction 'Lymphopenia'? | Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which ma... | Fatal | ReactionOutcome | CC BY | 34078415 | 19,713,405 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metabolic alkalosis'. | The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia.
Coronavirus disease 2019 (COVID-19) may result in a life-threatening condition due to a hyperactive immune reaction to severe acute respiratory syndrome-coronavirus-2 infection, for which no effective treatme... | FUROSEMIDE | DrugsGivenReaction | CC BY | 34078447 | 19,463,351 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory acidosis'. | The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia.
Coronavirus disease 2019 (COVID-19) may result in a life-threatening condition due to a hyperactive immune reaction to severe acute respiratory syndrome-coronavirus-2 infection, for which no effective treatme... | FUROSEMIDE | DrugsGivenReaction | CC BY | 34078447 | 19,463,351 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adrenal insufficiency'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34078988 | 20,038,386 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disseminated intravascular coagulation'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypopituitarism'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypothyroidism'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated enterocolitis'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated hyperthyroidism'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34078988 | 20,942,405 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated hypophysitis'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lymphocytic hypophysitis'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34078988 | 20,035,098 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Prescribed overdose'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyelonephritis'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory failure'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Secondary adrenocortical insufficiency'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY | 34078988 | 20,035,098 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Septic shock'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tubulointerstitial nephritis'. | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
What was the administration route of drug 'IPILIMUMAB'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Intravenous drip | DrugAdministrationRoute | CC BY | 34078988 | 20,035,098 | 2021-06-02 |
What was the administration route of drug 'NIVOLUMAB'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Intravenous drip | DrugAdministrationRoute | CC BY | 34078988 | 20,035,098 | 2021-06-02 |
What was the administration route of drug 'PEMBROLIZUMAB'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Intravenous drip | DrugAdministrationRoute | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
What was the dosage of drug 'IPILIMUMAB'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | 3 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
What was the dosage of drug 'NIVOLUMAB'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | 80 MILLIGRAM | DrugDosageText | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
What was the outcome of reaction 'Adrenal insufficiency'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Not recovered | ReactionOutcome | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
What was the outcome of reaction 'Diarrhoea'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Recovered | ReactionOutcome | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
What was the outcome of reaction 'Disseminated intravascular coagulation'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Recovering | ReactionOutcome | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
What was the outcome of reaction 'Hypothyroidism'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Not recovered | ReactionOutcome | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
What was the outcome of reaction 'Immune-mediated enterocolitis'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Recovering | ReactionOutcome | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
What was the outcome of reaction 'Immune-mediated hypophysitis'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Recovering | ReactionOutcome | CC BY | 34078988 | 16,897,650 | 2021-06-02 |
What was the outcome of reaction 'Pyelonephritis'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Recovering | ReactionOutcome | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
What was the outcome of reaction 'Respiratory failure'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Recovering | ReactionOutcome | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
What was the outcome of reaction 'Sepsis'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Recovering | ReactionOutcome | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
What was the outcome of reaction 'Septic shock'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Recovering | ReactionOutcome | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
What was the outcome of reaction 'Tubulointerstitial nephritis'? | Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adr... | Recovering | ReactionOutcome | CC BY | 34078988 | 15,772,509 | 2021-06-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | A Case of Paraneoplastic Pemphigus as a Preceding Manifestation of Underlying Follicular Lymphoma Treated with R-CHOP.
Paraneoplastic pemphigus is a rare, life-threatening disorder associated with an underlying neoplasm, which presents with painful stomatitis and polymorphous skin lesions. Successful diagnosis of paran... | CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC | 34079187 | 19,410,527 | 2021-06 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | A Case of Paraneoplastic Pemphigus as a Preceding Manifestation of Underlying Follicular Lymphoma Treated with R-CHOP.
Paraneoplastic pemphigus is a rare, life-threatening disorder associated with an underlying neoplasm, which presents with painful stomatitis and polymorphous skin lesions. Successful diagnosis of paran... | 6 CYCLES | DrugDosageText | CC BY-NC | 34079187 | 19,410,527 | 2021-06 |
What was the dosage of drug 'DOXORUBICIN'? | A Case of Paraneoplastic Pemphigus as a Preceding Manifestation of Underlying Follicular Lymphoma Treated with R-CHOP.
Paraneoplastic pemphigus is a rare, life-threatening disorder associated with an underlying neoplasm, which presents with painful stomatitis and polymorphous skin lesions. Successful diagnosis of paran... | 6 CYCLES | DrugDosageText | CC BY-NC | 34079187 | 19,410,527 | 2021-06 |
What was the dosage of drug 'RITUXIMAB'? | A Case of Paraneoplastic Pemphigus as a Preceding Manifestation of Underlying Follicular Lymphoma Treated with R-CHOP.
Paraneoplastic pemphigus is a rare, life-threatening disorder associated with an underlying neoplasm, which presents with painful stomatitis and polymorphous skin lesions. Successful diagnosis of paran... | 6 CYCLES | DrugDosageText | CC BY-NC | 34079187 | 19,410,527 | 2021-06 |
What was the dosage of drug 'VINCRISTINE'? | A Case of Paraneoplastic Pemphigus as a Preceding Manifestation of Underlying Follicular Lymphoma Treated with R-CHOP.
Paraneoplastic pemphigus is a rare, life-threatening disorder associated with an underlying neoplasm, which presents with painful stomatitis and polymorphous skin lesions. Successful diagnosis of paran... | 6 CYCLES | DrugDosageText | CC BY-NC | 34079187 | 19,410,527 | 2021-06 |
What was the outcome of reaction 'Respiratory failure'? | A Case of Paraneoplastic Pemphigus as a Preceding Manifestation of Underlying Follicular Lymphoma Treated with R-CHOP.
Paraneoplastic pemphigus is a rare, life-threatening disorder associated with an underlying neoplasm, which presents with painful stomatitis and polymorphous skin lesions. Successful diagnosis of paran... | Fatal | ReactionOutcome | CC BY-NC | 34079187 | 19,866,337 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemangioma'. | A Case Report of Multiple Capillary Hemangioma in a Chronic Myeloid Leukemia Patient Taking Tyrosine Kinase Inhibitors.
A capillary hemangioma is a vascular tumor with small capillary sized vascular channel. Multiple capillary hemangioma in relation with drugs have been rarely reported. Here in, we report a case of mul... | DASATINIB, IMATINIB MESYLATE | DrugsGivenReaction | CC BY-NC | 34079189 | 19,983,369 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | A Case Report of Multiple Capillary Hemangioma in a Chronic Myeloid Leukemia Patient Taking Tyrosine Kinase Inhibitors.
A capillary hemangioma is a vascular tumor with small capillary sized vascular channel. Multiple capillary hemangioma in relation with drugs have been rarely reported. Here in, we report a case of mul... | DASATINIB, IMATINIB MESYLATE | DrugsGivenReaction | CC BY-NC | 34079189 | 19,983,369 | 2021-06 |
What was the outcome of reaction 'Haemangioma'? | A Case Report of Multiple Capillary Hemangioma in a Chronic Myeloid Leukemia Patient Taking Tyrosine Kinase Inhibitors.
A capillary hemangioma is a vascular tumor with small capillary sized vascular channel. Multiple capillary hemangioma in relation with drugs have been rarely reported. Here in, we report a case of mul... | Recovering | ReactionOutcome | CC BY-NC | 34079189 | 19,983,369 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review.
Nivolumab (anti-PD-1) currently used in many cancers. With the usage of nivolumab increased, many cutaneous side effects were reported including maculopapular rash, lichenoid reactions, vitiligo, bullous disorders, psoriasis exacerbation, and alope... | NIVOLUMAB, TRIAMCINOLONE ACETONIDE | DrugsGivenReaction | CC BY-NC | 34079191 | 20,473,274 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood bilirubin increased'. | An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome.
During the recent years, immune checkpoint-based therapy has proven highly effective in microsatellite instable (MSI) solid tumors irrespective of organ site. MSI tumors are associated with a defective mismatch repair (MMR) system and a highly ... | ATEZOLIZUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34079322 | 19,478,067 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome.
During the recent years, immune checkpoint-based therapy has proven highly effective in microsatellite instable (MSI) solid tumors irrespective of organ site. MSI tumors are associated with a defective mismatch repair (MMR) system and a highly ... | ATEZOLIZUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34079322 | 19,478,067 | 2021 |
What was the administration route of drug 'PEMBROLIZUMAB'? | An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome.
During the recent years, immune checkpoint-based therapy has proven highly effective in microsatellite instable (MSI) solid tumors irrespective of organ site. MSI tumors are associated with a defective mismatch repair (MMR) system and a highly ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34079322 | 19,478,067 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Interstitial lung disease'. | A Rare Case of Pneumocystis Pneumonia in HIV Patient on Glucocorticoid.
Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii. PCP due to immunosuppressive drugs is rarely reported in the literature. Herein we present a case of PCP in a 49-year-old patient who presented with progre... | CEFTRIAXONE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY | 34079652 | 19,457,802 | 2021-04-13 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | A Rare Case of Pneumocystis Pneumonia in HIV Patient on Glucocorticoid.
Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii. PCP due to immunosuppressive drugs is rarely reported in the literature. Herein we present a case of PCP in a 49-year-old patient who presented with progre... | CEFTRIAXONE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY | 34079652 | 19,457,802 | 2021-04-13 |
What was the administration route of drug 'CEFTRIAXONE'? | A Rare Case of Pneumocystis Pneumonia in HIV Patient on Glucocorticoid.
Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii. PCP due to immunosuppressive drugs is rarely reported in the literature. Herein we present a case of PCP in a 49-year-old patient who presented with progre... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34079652 | 19,457,802 | 2021-04-13 |
What was the outcome of reaction 'Interstitial lung disease'? | A Rare Case of Pneumocystis Pneumonia in HIV Patient on Glucocorticoid.
Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii. PCP due to immunosuppressive drugs is rarely reported in the literature. Herein we present a case of PCP in a 49-year-old patient who presented with progre... | Recovered | ReactionOutcome | CC BY | 34079652 | 19,457,802 | 2021-04-13 |
What was the administration route of drug 'DONEPEZIL'? | Sick Sinus Syndrome Mimicking Autonomic Dysfunction of Dementia With Lewy Bodies.
Dementia with Lewy bodies (DLB) is recognized as the second most common form of dementia in aged people. It is well known that patients with DLB often develop various autonomic symptoms. Here, we present a case in which there was sick sin... | Oral | DrugAdministrationRoute | CC BY | 34079668 | 19,423,702 | 2021-04-24 |
What was the dosage of drug 'DONEPEZIL HYDROCHLORIDE'? | Sick Sinus Syndrome Mimicking Autonomic Dysfunction of Dementia With Lewy Bodies.
Dementia with Lewy bodies (DLB) is recognized as the second most common form of dementia in aged people. It is well known that patients with DLB often develop various autonomic symptoms. Here, we present a case in which there was sick sin... | 5 mg (milligrams). | DrugDosage | CC BY | 34079668 | 19,435,759 | 2021-04-24 |
What was the dosage of drug 'DONEPEZIL'? | Sick Sinus Syndrome Mimicking Autonomic Dysfunction of Dementia With Lewy Bodies.
Dementia with Lewy bodies (DLB) is recognized as the second most common form of dementia in aged people. It is well known that patients with DLB often develop various autonomic symptoms. Here, we present a case in which there was sick sin... | 5 mg (milligrams). | DrugDosage | CC BY | 34079668 | 19,423,702 | 2021-04-24 |
What was the dosage of drug 'PEROSPIRONE'? | Sick Sinus Syndrome Mimicking Autonomic Dysfunction of Dementia With Lewy Bodies.
Dementia with Lewy bodies (DLB) is recognized as the second most common form of dementia in aged people. It is well known that patients with DLB often develop various autonomic symptoms. Here, we present a case in which there was sick sin... | 4 mg (milligrams). | DrugDosage | CC BY | 34079668 | 19,435,770 | 2021-04-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | DACLIZUMAB, IMMUNE GLOBULIN NOS, METHYLPREDNISOLONE, RITUXIMAB | DrugsGivenReaction | CC BY-NC | 34079936 | 19,944,289 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | ACYCLOVIR, BORTEZOMIB, DEXAMETHASONE, HUMAN IMMUNOGLOBULIN G, LEVETIRACETAM, METHYLPREDNISOLONE, MIDAZOLAM, PERAMPANEL, PHENOBARBITAL, PHENYTOIN, RITUXIMAB, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY-NC | 34079936 | 19,642,679 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Somnolence'. | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | BORTEZOMIB, RISPERIDONE | DrugsGivenReaction | CC BY-NC | 34079936 | 19,946,409 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | BORTEZOMIB, RISPERIDONE | DrugsGivenReaction | CC BY-NC | 34079936 | 19,946,409 | 2021 |
What was the administration route of drug 'BORTEZOMIB'? | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34079936 | 19,642,679 | 2021 |
What was the administration route of drug 'DACLIZUMAB'? | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34079936 | 19,944,289 | 2021 |
What was the administration route of drug 'DEXAMETHASONE'? | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | Oral | DrugAdministrationRoute | CC BY-NC | 34079936 | 19,642,679 | 2021 |
What was the administration route of drug 'HUMAN IMMUNOGLOBULIN G'? | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34079936 | 19,642,679 | 2021 |
What was the administration route of drug 'IMMUNE GLOBULIN NOS'? | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34079936 | 19,944,289 | 2021 |
What was the dosage of drug 'ACYCLOVIR'? | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | UNK UNK, QD | DrugDosageText | CC BY-NC | 34079936 | 19,642,679 | 2021 |
What was the dosage of drug 'HUMAN IMMUNOGLOBULIN G'? | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | 2 GRAM PER KILOGRAM | DrugDosageText | CC BY-NC | 34079936 | 19,642,679 | 2021 |
What was the dosage of drug 'IMMUNE GLOBULIN NOS'? | Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic ... | 2 G/KG | DrugDosageText | CC BY-NC | 34079936 | 19,944,289 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal infection'. | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | COLISTIN, MEROPENEM | DrugsGivenReaction | CC BY-NC-ND | 34079986 | 20,740,745 | 2021-06-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bile duct necrosis'. | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | DAPTOMYCIN | DrugsGivenReaction | CC BY-NC-ND | 34079986 | 20,883,613 | 2021-06-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | CASPOFUNGIN, CEFIDEROCOL, COLISTIN, DAPTOMYCIN, LINEZOLID, MEROPENEM | DrugsGivenReaction | CC BY-NC-ND | 34079986 | 20,858,860 | 2021-06-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | CASPOFUNGIN, CEFIDEROCOL, COLISTIN, DAPTOMYCIN, LINEZOLID, MEROPENEM | DrugsGivenReaction | CC BY-NC-ND | 34079986 | 20,858,860 | 2021-06-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | COLISTIN, MEROPENEM | DrugsGivenReaction | CC BY-NC-ND | 34079986 | 20,740,745 | 2021-06-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | DAPTOMYCIN | DrugsGivenReaction | CC BY-NC-ND | 34079986 | 20,883,613 | 2021-06-03 |
What was the administration route of drug 'CASPOFUNGIN'? | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34079986 | 20,858,860 | 2021-06-03 |
What was the administration route of drug 'CEFIDEROCOL'? | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34079986 | 20,858,860 | 2021-06-03 |
What was the administration route of drug 'COLISTIN'? | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34079986 | 20,760,659 | 2021-06-03 |
What was the administration route of drug 'DAPTOMYCIN'? | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34079986 | 20,843,389 | 2021-06-03 |
What was the administration route of drug 'LINEZOLID'? | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34079986 | 20,843,389 | 2021-06-03 |
What was the outcome of reaction 'Abdominal infection'? | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | Fatal | ReactionOutcome | CC BY-NC-ND | 34079986 | 20,740,745 | 2021-06-03 |
What was the outcome of reaction 'Bile duct necrosis'? | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | Fatal | ReactionOutcome | CC BY-NC-ND | 34079986 | 20,883,613 | 2021-06-03 |
What was the outcome of reaction 'Sepsis'? | Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira.
We report a case of resistance development towards cefiderocol in a patient with intra-abdominal and bloodstream infections cau... | Fatal | ReactionOutcome | CC BY-NC-ND | 34079986 | 20,740,745 | 2021-06-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Clostridium test positive'. | Idiopathic Myointimal Hyperplasia of Mesenteric Veins (IMHMV) with two spontaneous bowel perforations: A case report and literature review.
Idiopathic myointimal hyperplasia of the mesenteric veins (IMHMV) is a poorly understood disorder which poses a diagnostic challenge to clinicians and pathologists. Here we have de... | ADALIMUMAB, HYDROCORTISONE, MESALAMINE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34082180 | 19,737,190 | 2021-06 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.